When Ray Kohn started feeling pain in his knees and elbows in 2015, he attributed it to his work as a stunt driver and mechanic. But as the years went on, he began to notice his body changing in ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) ...

Acromegaly is a rare endocrine disorder characterised by the excessive secretion of growth hormone (GH), most frequently resulting from a benign pituitary adenoma. The consequent overproduction of ...

Bone health is critically influenced by the balance of growth hormone signalling, with both growth hormone deficiency (GHD) and acromegaly demonstrating significant but contrasting impacts on the ...

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...